Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.nebraska.edu

Clinical Trials

Analysis of Lipid Biomarkers of Exposure and Host Response

Not Applicable

Terminated

Conditions: Cigarette Smoking

Interventions: Drug: nicotine polacrilex, transdermal system or inhaler

First Posted Date: 2007-06-28

Last Posted Date: 2023-09-07

Lead Sponsor: University of Nebraska

Target Recruit Count: 24

Registration Number: NCT00493831

Locations: 🇺🇸
Unversity of Nebraska Medical Center, Omaha, Nebraska, United States

Talabostat in Treating Patients With Metastatic Kidney Cancer

Phase 2

Withdrawn

Conditions: Kidney Cancer

Interventions: Drug: talabostat mesylate
Biological: enzyme inhibitor therapy
Diagnostic Test: flow cytometry
Diagnostic Test: laboratory biomarker analysis
Biological: non-specific immune-modulator therapy

First Posted Date: 2007-06-21

Last Posted Date: 2023-08-22

Lead Sponsor: University of Nebraska

Registration Number: NCT00489710

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

Phase 1

Completed

Conditions: Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Gastric Cancer
Liver Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: carboplatin
Drug: epirubicin hydrochloride
Genetic: microarray analysis
Genetic: polymorphism analysis
Other: pharmacological study

First Posted Date: 2007-06-14

Last Posted Date: 2024-01-03

Lead Sponsor: University of Nebraska

Target Recruit Count: 46

Registration Number: NCT00486356

Locations: 🇺🇸
University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: gemcitabine hydrochloride
Drug: imatinib mesylate
Genetic: mutation analysis
Genetic: nucleic acid sequencing
Genetic: polymerase chain reaction

First Posted Date: 2007-06-07

Last Posted Date: 2023-09-14

Lead Sponsor: University of Nebraska

Target Recruit Count: 13

Registration Number: NCT00483366

Locations: 🇺🇸
UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Gefitinib plus etoposide

First Posted Date: 2007-06-07

Last Posted Date: 2023-09-13

Lead Sponsor: University of Nebraska

Target Recruit Count: 26

Registration Number: NCT00483561

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: docetaxel
Drug: goserelin
Radiation: intensity-modulated radiation therapy

First Posted Date: 2007-06-05

Last Posted Date: 2023-11-24

Lead Sponsor: University of Nebraska

Target Recruit Count: 9

Registration Number: NCT00482807

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Analysis of Aldehyde Biomarkers of Exposure and Host Response

Not Applicable

Terminated

Conditions: Smoking Cessation

Interventions: Drug: nicotine polacrilex
Drug: nicotine transdermal system
Drug: nicotine inhaler

First Posted Date: 2007-06-05

Last Posted Date: 2023-09-07

Lead Sponsor: University of Nebraska

Target Recruit Count: 35

Registration Number: NCT00482690

Locations: 🇺🇸
Unversity of Nebraska Medical Center, Omaha, Nebraska, United States

Validation of Biomarkers of Exposure and Host Response

Not Applicable

Completed

Conditions: Cigarette Smoker

First Posted Date: 2007-05-02

Last Posted Date: 2023-08-31

Lead Sponsor: University of Nebraska

Target Recruit Count: 60

Registration Number: NCT00468234

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Vascular Risk After Kidney Transplantation

Completed

Conditions: Cardiovascular Disease
Chronic Kidney Disease
Diabetes
Hyperparathyroidism
Vitamin D Deficiency

First Posted Date: 2006-09-11

Last Posted Date: 2023-10-02

Lead Sponsor: University of Nebraska

Target Recruit Count: 338

Registration Number: NCT00374595

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children

Phase 4

Completed

Conditions: Attention Deficit Disorder With Hyperactivity

Interventions: Drug: Atomoxetine
Drug: Placebo
Behavioral: Parent Training

First Posted Date: 2005-11-16

Last Posted Date: 2023-10-02

Lead Sponsor: University of Nebraska

Target Recruit Count: 93

Registration Number: NCT00254462

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy